CNS Drugs

, Volume 19, Supplement 1, pp 1–93 | Cite as

Second-Generation (Atypical) Antipsychotics and Metabolic Effects

A Comprehensive Literature Review
Review Article


Increasing numbers of reports concerning diabetes, ketoacidosis, hyperglycaemia and lipid dysregulation in patients treated with second-generation (or atypical) antipsychotics have raised concerns about a possible association between these metabolic effects and treatment with these medications. This comprehensive literature review considers the evidence for and against an association between glucose or lipid dysregulation and eight separate second-generation antipsychotics currently available in the US and/or Europe, specifically clozapine, olanzapine, risperi-done, quetiapine, zotepine, amisulpride, ziprasidone and aripiprazole. This review also includes an assessment of the potential contributory role of treatment-induced weight gain in conferring risk for hyperglycaemia and dyslipidaemia during treatment with different antipsychotic medications.

Substantial evidence from a variety of human populations, including some recent confirmatory evidence in treated psychiatric patients, indicates that increased adiposity is associated with a variety of adverse physiological effects, including decreases in insulin sensitivity and changes in plasma glucose and lipid levels. Comparison of mean weight changes and relative percentages of patients experiencing specific levels of weight increase from controlled, randomised clinical trials indicates that weight gain liability varies significantly across the different second-generation antipsychotic agents. Clozapine and olanzapine treatment are associated with the greatest risk of clinically significant weight gain, with other agents producing relatively lower levels of risk. Risperidone, quetiapine, amisulpride and zotepine generally show low to moderate levels of mean weight gain and a modest risk of clinically significant increases in weight. Ziprasidone and aripiprazole treatment are generally associated with minimal mean weight gain and the lowest risk of more significant increases.

Published studies including uncontrolled observations, large retrospective database analyses and controlled experimental studies, including randomised clinical trials, indicate that the different second-generation antipsychotics are associated with differing effects on glucose and lipid metabolism. These studies offer generally consistent evidence that clozapine and olanzapine treatment are associated with an increased risk of diabetes mellitus and dyslipidaemia. Inconsistent results, and a generally smaller effect in studies where an effect is reported, suggest limited if any increased risk for treatment-induced diabetes mellitus and dyslipidaemia during risperidone treatment, despite a comparable volume of published data. A similarly smaller and inconsistent signal suggests limited if any increased risk of diabetes or dyslipidaemia during quetiapine treatment, but this is based on less published data than is available for risperidone. The absence of retrospective database studies, and little or no relevant published data from clinical trials, makes it difficult to draw conclusions concerning risk for zotepine or amisulpride, although amisulpride appears to have less risk of treatment-emergent dyslipidaemia in comparison to olanzapine. With increasing data from clinical trials but little or no currently published data from large retrospective database analyses, there is no evidence at this time to suggest that ziprasidone and aripiprazole treatment are associated with an increase in risk for diabetes, dyslipidaemia or other adverse effects on glucose or lipid metabolism.

In general, the rank order of risk observed for the second-generation antipsychotic medications suggests that the differing weight gain liability of atypical agents contributes to the differing relative risk of insulin resistance, dyslipidaemia and hyperglycaemia. This would be consistent with effects observed in nonpsychiatric samples, where risk for adverse metabolic changes tends to increase with increasing adiposity. From this perspective, a possible increase in risk would be predicted to occur in association with any treatment that produces increases in weight and adiposity. However, case reports tentatively suggest that substantial weight gain or obesity may not be a factor in up to one-quarter of cases of new-onset diabetes that occur during treatment. Pending further testing from preclinical and clinical studies, limited controlled studies support the hypothesis that clozapine and olanzapine may have a direct effect on glucose regulation independent of adiposity. The results of studies in this area are relevant to primary and secondary prevention efforts that aim to address the multiple factors that contribute to increased prevalence of type 2 diabetes mellitus and cardiovascular disease in populations that are often treated with second-generation antipsychotic medications.


  1. 1.
    International Obesity TaskForce and the European Association for the Study of Obesity. Obesity in Europe: the case for action. IOTF in collaboration with EASO. London, September 2002 [online]. Available from: URL: [Accessed 23 November 2004]
  2. 2.
    Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341(15): 1097–105CrossRefGoogle Scholar
  3. 3.
    NIH/NHLBI guidelines. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report. NIH Publication No. 98-4084. Bethesda, MD: National Institutes of Health, 1998 SepGoogle Scholar
  4. 4.
    Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. JAMA 1999; 282(16): 1530–8PubMedCrossRefGoogle Scholar
  5. 5.
    Minino AM, Arias E, Kochanek KD, et al. Deaths: final data for 2000. Natl Vital Stat Rep 2002; 50(15): 1–119PubMedGoogle Scholar
  6. 6.
    Willett WC, Manson JE, Stampfer MJ, et al. Weight, weight change, and coronary heart disease in women. Risk within the ’normal’ weight range. JAMA 1995; 273: 461–5Google Scholar
  7. 7.
    Shaper AG, Wannamethee SG, Walker M. Body weight: implications for the prevention of coronary heart disease, stroke, and diabetes mellitus in a cohort study of middle aged men. BMJ 1997; 314: 1311–7PubMedCrossRefGoogle Scholar
  8. 8.
    Shimizu M, Isogai Y. Heart failure due to metabolic heart disorders. Nippon Rinsho 1993; 51: 1362–6PubMedGoogle Scholar
  9. 9.
    Rexrode KM, Hennekens CH, Willett WC, et al. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA 1997; 277: 1539–45PubMedCrossRefGoogle Scholar
  10. 10.
    Walker SP, Rimm EB, Ascherio A, et al. Body size and fat distribution as predictors of stroke among US men. Am J Epidemiol 1996; 144: 1143–50PubMedCrossRefGoogle Scholar
  11. 11.
    Colditz GA, Willett WC, Stampfer MJ, et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 1990; 132: 501–13PubMedGoogle Scholar
  12. 12.
    Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481–6PubMedGoogle Scholar
  13. 13.
    Brown CD, Higgins M, Donato KA, et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 2000; 8(9): 605–19PubMedCrossRefGoogle Scholar
  14. 14.
    Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993; 119 (7 pt 2): 655–60PubMedGoogle Scholar
  15. 15.
    Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes and obesity-related health risk factors, 2001. JAMA 2003; 289: 76–9PubMedCrossRefGoogle Scholar
  16. 16.
    Despres JP. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition 1993; 9(5): 452–9PubMedGoogle Scholar
  17. 17.
    Banjeri M, Chaiken R, Gordon D, Lebowitz H. Does intra-abdominal tissue in black men determine whether NIDDM is insulin-resistant or insulin-sensitive? Diabetes 1995; 44: 141–5CrossRefGoogle Scholar
  18. 18.
    Goodpaster BH, Kelly DE, Wing RR, et al. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 1999; 48: 839–47PubMedCrossRefGoogle Scholar
  19. 19.
    Kelly DE, Goodpaster BH. Skeletal muscle triglyceride. An aspect of regional adiposity and insulin resistance. Diabetes Care 2001; 24(5): 933–41Google Scholar
  20. 20.
    Goldstein BJ. Insulin resistance: from benign to type 2 diabetes mellitus. Rev Cardiovasc Med 2003; 4(Suppl 6): S3–S10PubMedGoogle Scholar
  21. 21.
    Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2002. Atlanta (GA): US Department of Health and Human Services, Centers for Disease Control and Prevention, 2003Google Scholar
  22. 22.
    World Health Organization. Atlas of Health in Europe. Geneva: World Health Organization, 2003Google Scholar
  23. 23.
    Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. Diabetes Care 1998; 21: 518–24PubMedCrossRefGoogle Scholar
  24. 24.
    DECODE Study Group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 2003; 26: 61–9CrossRefGoogle Scholar
  25. 25.
    Gu K, Cowie C, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971–1993. Diabetes Care 1998; 21: 1138–45PubMedCrossRefGoogle Scholar
  26. 26.
    American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 2003; 26: 917–32CrossRefGoogle Scholar
  27. 27.
    Jonsson B, CODE-2 Advisory Board. Revealing the cost of type II diabetes in Europe. Diabetologia 2002; 45(7): S5–12PubMedCrossRefGoogle Scholar
  28. 28.
    Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183–97Google Scholar
  29. 29.
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27Suppl 1: S5–S10Google Scholar
  30. 30.
    Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003; 26 Suppl 1: S5–S20Google Scholar
  31. 31.
    Lebovitz HE. Diagnosis, classification, and pathogenesis of diabetes mellitus. J Clin Psychiatry 2001; 62 Suppl 27: 5–9Google Scholar
  32. 32.
    Schwartz MW. Staying slim with insulin in mind. Science 2000; 289: 2066–7PubMedCrossRefGoogle Scholar
  33. 33.
    Brüning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289: 2122–5PubMedCrossRefGoogle Scholar
  34. 34.
    NCEP Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25): 3143–421Google Scholar
  35. 35.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326): 7–22CrossRefGoogle Scholar
  36. 36.
    Sanoski CA. Management of dyslipidemia: an update. Curr Atheroscler Rep 2003; 5(4): 284–90PubMedCrossRefGoogle Scholar
  37. 37.
    Grundy SM, Cleeman JI, Merz CN, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110(2): 227–39PubMedCrossRefGoogle Scholar
  38. 38.
    Cohn G, Valdes G, Capuzzi DM. Pathophysiology and treatment of the dyslipidemia of insulin resistance. Curr Cardiol Rep 2001; 3: 416–23PubMedCrossRefGoogle Scholar
  39. 39.
    Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease. Am J Clin Nutr 1956; 4: 20–34PubMedGoogle Scholar
  40. 40.
    Reaven G. Banting lecture 1988: Role of insulin resistance in human disease. Diabetologia 1988; 30: 1595–607Google Scholar
  41. 41.
    Reaven G. Syndrome X: 10 years after. Drugs 1999; 58 Suppl 1: 19–20; discussion 75-82CrossRefGoogle Scholar
  42. 42.
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–9PubMedCrossRefGoogle Scholar
  43. 43.
    Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24(4): 683–9PubMedCrossRefGoogle Scholar
  44. 44.
    Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004; 24 5Suppl 1: S1–S6CrossRefGoogle Scholar
  45. 45.
    Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999; 29: 697–701PubMedCrossRefGoogle Scholar
  46. 46.
    Baxter DN. The mortality experience of individuals on the Salford case register. I. All-cause mortality. Br J Psychiatry 1996; 168: 772–9Google Scholar
  47. 47.
    Hennekens CH. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation 1998; 97: 1095–102PubMedCrossRefGoogle Scholar
  48. 48.
    Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 2001; 50: 71–83PubMedCrossRefGoogle Scholar
  49. 49.
    Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999; 60(4): 215–20PubMedCrossRefGoogle Scholar
  50. 50.
    Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997; 171: 502–8CrossRefGoogle Scholar
  51. 51.
    Ösby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000; 45(1-2): 21–8PubMedCrossRefGoogle Scholar
  52. 52.
    Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord 2002; 68(2-3): 167–81PubMedCrossRefGoogle Scholar
  53. 53.
    Cuijpers P, Smit F. Excess mortality in depression: a meta-analysis of community studies. J Affect Disord 2002; 72(3): 227–36PubMedCrossRefGoogle Scholar
  54. 54.
    Haupt DW, Newcomer JW. Abnormalities in glucose regulation associated with mental illness and treatment. J Psychosom Res 2002; 53(4): 925–33PubMedCrossRefGoogle Scholar
  55. 55.
    Tabata H, Kikuoka M, Kikuoka H, et al. Characteristics of diabetes mellitus in schizophrenic patients. J Med Assoc Thai 1987; 70 Suppl 2: 90–3Google Scholar
  56. 56.
    Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996; 37: 68–73PubMedCrossRefGoogle Scholar
  57. 57.
    Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26: 903–12PubMedCrossRefGoogle Scholar
  58. 58.
    Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286: 1195–200PubMedCrossRefGoogle Scholar
  59. 59.
    Allison DB, Mentore LJ, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96PubMedGoogle Scholar
  60. 60.
    Regenold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. [Erratum in: J Affect Disord 2003; 73(3): 301-2] J Affect Disord 2002; 70: 19–26PubMedCrossRefGoogle Scholar
  61. 61.
    Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug naive patients with schizophrenia. Am J Psychiatry 2003; 160(2): 284–9PubMedCrossRefGoogle Scholar
  62. 62.
    Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Rev Arch Gen Psychiatry 2002; 59: 337–45CrossRefGoogle Scholar
  63. 63.
    Ryan MC, Flanagan S, Kinsella U, et al. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004; 74(16): 1999–2008PubMedCrossRefGoogle Scholar
  64. 64.
    Chiba M, Suzuki S, Hinokio Y, et al. Tyrosine hydroxylase gene microsatellite polymorphism associated with insulin resistance in depressive disorder. Metabolism 2000; 49(9): 1145–9PubMedCrossRefGoogle Scholar
  65. 65.
    Okamura F, Tashiro A, Utumi A, et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 2000; 49(10): 1255–60PubMedCrossRefGoogle Scholar
  66. 66.
    Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70(1): 1–17PubMedCrossRefGoogle Scholar
  67. 67.
    Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999; 100(1): 3–16PubMedCrossRefGoogle Scholar
  68. 68.
    American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27(2): 596–601CrossRefGoogle Scholar
  69. 69.
    Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med 2001; 111: 716–23PubMedCrossRefGoogle Scholar
  70. 70.
    Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus [review]. Pharmacotherapy 2002; 22: 841–52PubMedCrossRefGoogle Scholar
  71. 71.
    Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003; 23(6): 735–44PubMedCrossRefGoogle Scholar
  72. 72.
    Henderson DC, Cagliero E, Copeland P, et al. Glucose metabolism in schizophrenia patients with atypical antipsychotic: a frequent sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005; 62(1): 19–28PubMedCrossRefGoogle Scholar
  73. 73.
    Ebenbichler CF, Laimer M, Eder U, et al. Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry 2003; 64: 1436–9PubMedCrossRefGoogle Scholar
  74. 74.
    Jones AM, Rak IW, Raniwalla J. Weight changes in patients treated with quetiapine. Poster presented at the 153rd Annual Meeting of the American Psychiatric Association, May 13–18, 2000, Chicago, ILGoogle Scholar
  75. 75.
    Leucht S, Wagenpfeil S, Hamann J, Kissling W. Amisulpride is an “atypical” antipsychotic associated with low weight gain. Psychopharmacology 2004; 173: 112–5PubMedCrossRefGoogle Scholar
  76. 76.
    Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term placebo-controlled trials. SchizophrRes 2003; 61: 123–36CrossRefGoogle Scholar
  77. 77.
    Boehm G, Racoosin JA, Laughren TP, Katz R. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. Diabetes Care 2004; 27(8): 2088–9PubMedCrossRefGoogle Scholar
  78. 78.
    Kemner C, Willemsen-Swinkels SH, de Jonge M, et al. Open label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 2002; 22: 455–60PubMedCrossRefGoogle Scholar
  79. 79.
    Ercan ES, Kutlu A, Varan A, et al. Olanzapine treatment of eight adolescent patients with psychosis. Hum Psychopharmacol 2004; 19: 53–6PubMedCrossRefGoogle Scholar
  80. 80.
    Scahill L, Leckman JF, Schultz RT, et al. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003; 60: 1130–5PubMedCrossRefGoogle Scholar
  81. 81.
    Patel NC, Kistler JS, James EB, Crismon ML. A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents. Pharmacotherapy 2004; 24: 824–30PubMedCrossRefGoogle Scholar
  82. 82.
    Aman MG, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002; 159: 1337–46PubMedCrossRefGoogle Scholar
  83. 83.
    Gilbert DL, Batterson JR, Sethuraman G, Sallee FR. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry 2004; 43: 206–14PubMedCrossRefGoogle Scholar
  84. 84.
    Gagliano A, Germano E, Pustorino G, et al. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol 2004; 14: 39–47PubMedCrossRefGoogle Scholar
  85. 85.
    McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347: 314–21PubMedCrossRefGoogle Scholar
  86. 86.
    Martin A, Scahill L, Anderson GM, et al. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 2004; 161: 1125–7PubMedCrossRefGoogle Scholar
  87. 87.
    Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004; 29: 133–45PubMedCrossRefGoogle Scholar
  88. 88.
    Visser M, Pahor M, Tylavsky F, et al. One- and two-year change in body composition as measured by DXA in a population-based cohort of older men and women. J Appl Physiol 2003; 94: 2368–74PubMedCrossRefGoogle Scholar
  89. 89.
    Gallagher D, Ruts E, Visser M, et al. Weight stability masks sarcopenia in elderly men and women. Am J Physiol Endocrinol Metab 2000; 279: E366–75PubMedGoogle Scholar
  90. 90.
    Barak Y, Shamir E, Weizman R. Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective, comparative study. J Clin Psychopharmacol 2002; 22: 115–20PubMedCrossRefGoogle Scholar
  91. 91.
    Barak Y. No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. J Clin Psychiatry 2002; 63: 117–9PubMedCrossRefGoogle Scholar
  92. 92.
    Goldberg R. Weight variance associated with atypical neuroleptics in nursing home dementia patients. J Am Med Dir Assoc 2001; 2(1): 26–8PubMedCrossRefGoogle Scholar
  93. 93.
    Madhusoodanan S, Suresh P, Brenner R, Pillai R. Experience with the atypical antipsychotics —risperidone and olanzapine in the elderly. Ann Clin Psychiatry 1999; 11: 113–8PubMedGoogle Scholar
  94. 94.
    Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000; 57: 968–76CrossRefGoogle Scholar
  95. 95.
    Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003; 28(3): 519–26PubMedCrossRefGoogle Scholar
  96. 96.
    Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002; 359(9323): 2086–7PubMedCrossRefGoogle Scholar
  97. 97.
    Reynolds GP, Zhang Z, Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003; 160(4): 677–9PubMedCrossRefGoogle Scholar
  98. 98.
    Theisen FM, Hinney A, Bromel T, et al. Lack of association between the −759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals. Psychiatr Genet 2004; 14(3): 139-42PubMedCrossRefGoogle Scholar
  99. 99.
    Taylor DM, McAskill R. Atypical antipsychotics and weight gain — a systematic review. Acta Psychiatr Scand 2000; 101(6): 416–32PubMedCrossRefGoogle Scholar
  100. 100.
    Eder U, Mangweth B, Ebenbichler C, et al. Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 2001; 158: 1719–22PubMedCrossRefGoogle Scholar
  101. 101.
    Dwyer DS, Pinkofsky HB, Liu Y, Bradley RJ. Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells. Prog Neuropsychopharmacol Biol Psychiatry 1999; 23(1): 69–80PubMedCrossRefGoogle Scholar
  102. 102.
    Ardizzone TD, Bradley RJ, Freeman 3rd AM, Dwyer DS. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res 2001; 923(1-2): 82–90PubMedCrossRefGoogle Scholar
  103. 103.
    Dwyer DS, Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav 2003; 75(2): 255–60PubMedCrossRefGoogle Scholar
  104. 104.
    Elman I, Goldstein DS, Eisenhofer G, et al. Mechanism of peripheral noradrenergic stimulation by clozapine. Neuropsychopharmacology 1999; 20(1): 29–34PubMedCrossRefGoogle Scholar
  105. 105.
    Spivak B, Roitman S, Vered Y, et al. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol 1998; 21: 245–50PubMedGoogle Scholar
  106. 106.
    Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001; 62 Suppl 27: 15–26; discussion 40-1Google Scholar
  107. 107.
    Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 1968; 124(7): 978–82PubMedGoogle Scholar
  108. 108.
    Clark M, Dubowski K, Colmore J. The effect of chlorpro-mazine on serum cholesterol in chronic schizophrenic patients. Clin Pharmacol Ther 1970; 11: 883–9PubMedGoogle Scholar
  109. 109.
    Amdisen A. Drug-produced obesity: experiences with chlor-promazine, perphenazine and clopenthixol. Dan Med Bull 1964; 11: 182–9PubMedGoogle Scholar
  110. 110.
    Blin O. A comparative review of new antipsychotics. Can J Psychiatry 1999; 44(3): 235–44PubMedGoogle Scholar
  111. 111.
    Leadbetter R, Shutty M, Pavalonis D, et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992; 149(1): 68–72PubMedGoogle Scholar
  112. 112.
    Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992; 149(5): 689–90PubMedGoogle Scholar
  113. 113.
    Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358–63PubMedCrossRefGoogle Scholar
  114. 114.
    Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157: 975–81PubMedCrossRefGoogle Scholar
  115. 115.
    Iqbal MM, Rahman A, Husain Z, et al. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 2003; 15(1): 33–48PubMedGoogle Scholar
  116. 116.
    Bustillo JR, Buchanan RW, Irish D, Breier A. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 1996; 153(6): 817–9PubMedGoogle Scholar
  117. 117.
    Wehring HJ, Kelly DL, Love RC, Conley RR. Deaths from diabetic ketoacidosis after long term clozapine treatment. Am J Psychiatry 2003; 160(12): 2241–2PubMedCrossRefGoogle Scholar
  118. 118.
    Beliard S, Valero R, Vialettes B. Atypical neuroleptics and diabetes. Diabetes Metab 2003; 29(3): 296–9PubMedCrossRefGoogle Scholar
  119. 119.
    Lafayette JM, Pirl WF, Henderson DC. Low-dose clozapine and diabetic ketoacidosis. Psychosomatics 2003; 44(3): 249-52PubMedCrossRefGoogle Scholar
  120. 120.
    Cohen D, Gispen-de Wied CC. Schizophrenia and diabetes mellitus: not an improbable combination [in Dutch]. Tijdschr Geneeskd 2003; 147(21): 993–6Google Scholar
  121. 121.
    Kristensen SH, Porksen NK. Clozapine and diabetic ketoacidosis [in Danish]. Ugeskr Laeger 2003; 165(5): 475–6PubMedGoogle Scholar
  122. 122.
    Avram AM, Patel V, Taylor HC, et al. Euglycemic clamp study in clozapine-induced diabetic ketoacidosis. Ann Pharmacother 2001;35: 1381–7PubMedCrossRefGoogle Scholar
  123. 123.
    Rigalleau V, Gatta B, Bonnaud S, et al. Diabetes as a result of atypical anti-psychotic drugs—a report of three cases. Diabet Med 2000; 17: 484–6PubMedCrossRefGoogle Scholar
  124. 124.
    Wu G, Dias P, Chun W, et al. Hyperglycemia, hyperlipemia, and periodic paralysis: a case report of new side effects of clozapine. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24: 1395–400PubMedCrossRefGoogle Scholar
  125. 125.
    Isakov I, Klesmer J, Masand PS. Insulin-resistant hyperglycemia induced by clozapine [letter]. Psychosomatics 2000; 41: 373–4PubMedCrossRefGoogle Scholar
  126. 126.
    Wehring H, Alexander B, Perry PJ. Diabetes mellitus associated with clozapine therapy. Pharmacotherapy 2000; 20: 844–7PubMedCrossRefGoogle Scholar
  127. 127.
    Brugman NJ, Cohen D, de Vries RH. Diabetes mellitus after treatment with clozapine [in Dutch]. Ned Tijdschr Geneeskd 2000; 144(9): 437–9PubMedGoogle Scholar
  128. 128.
    Maule S, Giannella R, Lanzio M, Villari V. Diabetic ketoacidosis with clozapine treatment [letter]. Diabetes Nutr Metab 1999; 12: 187–8PubMedGoogle Scholar
  129. 129.
    Colli A, Cocciolo M, Francobandiera F, et al. Diabetic ketoacidosis associated with clozapine treatment [letter]. Diabetes Care 1999; 22: 176–7PubMedCrossRefGoogle Scholar
  130. 130.
    Mohan D, Gordon H, Hindley N, Barker A. Schizophrenia and diabetes mellitus [letter]. Br J Psychiatry 1999; 174: 180–1PubMedCrossRefGoogle Scholar
  131. 131.
    Smith H, Kenney-Herbert J, Knowles L. Clozapine-induced diabetic ketoacidosis [letter]. Aust N Z J Psychiatry 1999; 33: 120–1PubMedCrossRefGoogle Scholar
  132. 132.
    Ai D, Roper TA, Riley JA. Diabetic ketoacidosis and clozapine. Postgrad Med J 1998; 74(874): 493–4PubMedCrossRefGoogle Scholar
  133. 133.
    Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44: 778–83PubMedCrossRefGoogle Scholar
  134. 134.
    Dickson RA, Hogg L. Pregnancy of a patient treated with clozapine. Psychiatr Serv 1998; 49: 1081–3PubMedGoogle Scholar
  135. 135.
    Thompson J, Chengappa KN, Good CB, et al. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment. Int Clin Psychopharmacol 1998; 13: 95–8PubMedCrossRefGoogle Scholar
  136. 136.
    Pierides M. Clozapine monotherapy and ketoacidosis. Br J Psychiatry 1997; 171: 90–1PubMedCrossRefGoogle Scholar
  137. 137.
    Popli AP, Konicki PE, Jurjus GJ, et al. Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997; 58: 108–11PubMedCrossRefGoogle Scholar
  138. 138.
    Koren W, Kreis Y, Duchowiczny K, et al. Lactic acidosis and fatal myocardial failure due to clozapine. Ann Pharmacother 1997; 31: 168–70PubMedGoogle Scholar
  139. 139.
    Peterson GA, Byrd SL. Diabetic ketoacidosis from clozapine and lithium cotreatment [letter]. Am J Psychiatry 1996; 153: 737–8PubMedGoogle Scholar
  140. 140.
    Kostakoglu AE, Yazici KM, Erbas T, Guvener N. Ketoacidosis as a side-effect of clozapine: a case report. Acta Psychiatr Scand 1996; 93: 217–8PubMedCrossRefGoogle Scholar
  141. 141.
    Koval MS, Rames LJ, Christie S. Diabetic ketoacidosis associated with clozapine treatment [letter]. Am J Psychiatry 1994; 151: 1520–1PubMedGoogle Scholar
  142. 142.
    Kamran A, Doraiswamy PM, Jane JL, et al. Severe hyperglycemia associated with high doses of clozapine [letter]. Am J Psychiatry 1994; 151: 1395PubMedGoogle Scholar
  143. 143.
    Ananth J, Venkatesh R, Burgoyne K, Gunatilake S. Atypical antipsychotic drug use and diabetes. Psychother Psychosom 2002; 71: 244–54PubMedCrossRefGoogle Scholar
  144. 144.
    Baymiller SP, Ball P, McMahon RP, Buchanan RW. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res 2003; 59: 49–57PubMedCrossRefGoogle Scholar
  145. 145.
    Hägg S, Joelsson L, Mjorndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998; 59: 294–9PubMedCrossRefGoogle Scholar
  146. 146.
    Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63: 856–65PubMedCrossRefGoogle Scholar
  147. 147.
    Kurt E, Oral ET. Antipsychotics and glucose, insulin, lipids, prolactin, uric acid metabolism in schizophrenia [abstract]. Eur Neuropsychopharmacol 2002; 12Suppl 3: S276, P.2.049CrossRefGoogle Scholar
  148. 148.
    Chae BJ, Kang BJ. The effect of clozapine on blood glucose metabolism. Hum Psychopharmacol 2001; 16: 265–71PubMedCrossRefGoogle Scholar
  149. 149.
    Melkersson KI, Hulting AL. Insulin and leptin levels in patients with schizophrenia or related psychoses — a comparison between different antipsychotic agents. Psychopharmacology (Berl)2001; 154: 205–12CrossRefGoogle Scholar
  150. 150.
    Yazici KM, Erbas T, Yazici AH. The effect of clozapine on glucose metabolism. Exp Clin Endocrinol Diabetes 1998; 106: 475–7PubMedCrossRefGoogle Scholar
  151. 151.
    Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl) 2003; 170(2): 157–66CrossRefGoogle Scholar
  152. 152.
    Melkersson KI, Hulting AL, Brismar KE. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 1999; 60: 783–91PubMedCrossRefGoogle Scholar
  153. 153.
    Chue P, Welch R. Investigation of the metabolic effects of antipsychotics in patients with schizophrenia [abstract]. Eur Neuropsychopharmacol 2003; 13Suppl 4: S300, P.2.049CrossRefGoogle Scholar
  154. 154.
    Howes OD, Bhatnagar A, Gaughran F, et al. The effect of clozapine on factors controlling glucose homeostasis [abstract]. Schizophr Res 2004; 67: 186, no. 377Google Scholar
  155. 155.
    Sernyak MJ, Gulanski B, Leslie DL, Rosenheck R. Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. J Clin Psychiatry 2003; 64(5): 605–8PubMedCrossRefGoogle Scholar
  156. 156.
    Gupta S, Steinmeyer C, Frank B, et al. Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy. Am J Ther 2003; 10(5): 348–55PubMedCrossRefGoogle Scholar
  157. 157.
    Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159(4): 561–6PubMedCrossRefGoogle Scholar
  158. 158.
    Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 2001; 58(4): 1172–6PubMedCrossRefGoogle Scholar
  159. 159.
    Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002; 63: 920–30PubMedCrossRefGoogle Scholar
  160. 160.
    Lambert B, Chou C-H, Chang K-Y, et al. Assessing the risk of antipsychotic-induced type II diabetes among schizophrenics: a matched case-control study [abstract]. Eur Neuropsychopharmacol 2002; 12Suppl 3: S307, P.2.126CrossRefGoogle Scholar
  161. 161.
    Citrome L, Jaffe A, Levine J, et al. Antipsychotic medication treatment and new prescriptions for insulin and oral hypoglycemics [abstract]. Eur Neuropsychopharmacol 2003; 13Suppl 4: S306, P.2.063CrossRefGoogle Scholar
  162. 162.
    Wang PS, Glynn RJ, Ganz DA, et al. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol 2002; 22: 236–43PubMedCrossRefGoogle Scholar
  163. 163.
    Buse JB, Cavazzoni P, Hornbuckle K, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003; 56(2): 164–70PubMedCrossRefGoogle Scholar
  164. 164.
    Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160: 290–6PubMedCrossRefGoogle Scholar
  165. 165.
    Rettenbacher MA, Baumgartner S, Ebenbichler C, et al. Alterations of glucose metabolism under treatment with clozapine vs. amisulpride [abstract]. Schizophr Res 2004; 67: 191, no. 390Google Scholar
  166. 166.
    Kenny SJ, Aubert RE, Geiss LS. Prevalence and incidence of non-insulin dependent diabetes. In: Harris MI, Cowie CC, Stern MP, et al., eds. Diabetes in America, 2nd ed. Publication no. 95-1468. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995: 47–67Google Scholar
  167. 167.
    Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001; 62 Suppl 23: 5–12Google Scholar
  168. 168.
    Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233–40Google Scholar
  169. 169.
    Gerstein HC. Is glucose a continuous risk factor for cardiovascular mortality? Diabetes Care 1999; 22: 659–60PubMedCrossRefGoogle Scholar
  170. 170.
    Temelkova-Kurktschiev T, Henkel E, Schaper F, et al. Prevalence and atherosclerosis risk in different types of non-diabetic hyperglycemia. Is mild hyperglycemia an underestimated evil? Exp Clin Endocrinol Diabetes 2000; 108: 93–9CrossRefGoogle Scholar
  171. 171.
    Gaulin BD, Markowitz JS, Caley CF, et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999; 156: 1270–2PubMedGoogle Scholar
  172. 172.
    Spivak B, Lamschtein C, Talmon Y, et al. The impact of clozapine treatment on serum lipids in chronic schizophrenic patients. Clin Neuropharmacol 1999; 22: 98–101PubMedCrossRefGoogle Scholar
  173. 173.
    Ghaeli P, Dufresne RL. Elevated serum triglycerides with clozapine resolved with risperidone in four patients. Pharmacotherapy 1999; 19: 1099–101PubMedCrossRefGoogle Scholar
  174. 174.
    Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 1996; 53: 2079–81PubMedGoogle Scholar
  175. 175.
    Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003; 64(5): 598–604PubMedCrossRefGoogle Scholar
  176. 176.
    Dursun SM, Szemis A, Andrews H, Reveley MA. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. J Psychiatry Neurosci 1999; 24: 453–5PubMedGoogle Scholar
  177. 177.
    Gupta S, Droney T, Al-Samarrai S, et al. Olanzapine: weight gain and therapeutic efficacy. J Clin Psychopharmacol 1999; 19(3): 273–5PubMedCrossRefGoogle Scholar
  178. 178.
    Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997; 58 Suppl 10: 45–9Google Scholar
  179. 179.
    Beasley CM, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry 1997; 58(Suppl 10)1 3–17Google Scholar
  180. 180.
    Kurzthaler I, Fleischhacker WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 2001; 62 Suppl 7: 32–7Google Scholar
  181. 181.
    Ader M, Catalano KJ, Ionut V, et al. Differential metabolic effects between atypical antipsychotics in normal dogs. Poster presented at the American Diabetes Association 63rd Scientific Sessions, June 13–17, 2003, New Orleans, LAGoogle Scholar
  182. 182.
    Biswas PN, Wilton LV, Pearcel GL, et al. The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacol 2001; 15: 265–71CrossRefGoogle Scholar
  183. 183.
    Torrey EF, Swalwell CI. Fatal olanzapine-induced ketoacidosis. Am J Psychiatry 2003; 160(12): 2241PubMedCrossRefGoogle Scholar
  184. 184.
    Dewan V. Potential risk of diabetes mellitus with the use of atypical antipsychotic medication. Can J Psychiatry 2003; 48(5): 351–2PubMedGoogle Scholar
  185. 185.
    Tavakoli SA, Arguisola MS. Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine. South Med J 2003; 96(7): 729–30PubMedCrossRefGoogle Scholar
  186. 186.
    Chang HY, Ridky TW, Kimball AB, et al. Eruptive xanthomas associated with olanzapine use. Arch Dermatol 2003; 139(8): 1045–8PubMedCrossRefGoogle Scholar
  187. 187.
    Azriel Mira S. Uncontrolled hyperglycemia with ketosis associated with olanzapine therapy [in Spanish]. Rev Clin Esp 2002; 202: 672PubMedGoogle Scholar
  188. 188.
    Kozian R. Olanzapine-induced diabetes mellitus [in German]. Psychiatr Prax 2002; 29: 318–20PubMedCrossRefGoogle Scholar
  189. 189.
    Straker D, Mendelowitz A, Karlin L. Near fatal ketoacidosis with olanzapine treatment [letter]. Psychosomatics 2002; 43: 339–40PubMedCrossRefGoogle Scholar
  190. 190.
    Meatherall R, Younes J. Fatality from olanzapine induced hyperglycemia. J Forensic Sci 2002; 47: 893–6PubMedGoogle Scholar
  191. 191.
    Opp D, Hildebrandt C. Olanzapine-associated type 2 diabetes mellitus [letter]. Schizophr Res 2002; 56: 195–6PubMedCrossRefGoogle Scholar
  192. 192.
    Malyuk R, Gibson B, Procyshyn RM, Kang N. Olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome: case report. Int J Geriatr Psychiatry 2002; 17: 326–8PubMedCrossRefGoogle Scholar
  193. 193.
    Riccitelli G, Baker N. Weight gain and hyperglycaemia associated with olanzapine [letter]. Aust N Z J Psychiatry 2002; 36: 270–1PubMedGoogle Scholar
  194. 194.
    Ramankutty G. Olanzapine-induced destabilization of diabetes in the absence of weight gain. Acta Psychiatr Scand 2002; 105: 235–6; discussion 236-7PubMedCrossRefGoogle Scholar
  195. 195.
    Melkersson K, Hulting AL. Recovery from new-onset diabetes in a schizophrenic man after withdrawal of olanzapine. Psychosomatics 2002; 43: 67–70PubMedCrossRefGoogle Scholar
  196. 196.
    Ragucci KR, Wells BJ. Olanzapine-induced diabetic ketoacidosis. Ann Pharmacother 2001; 35: 1556–8PubMedCrossRefGoogle Scholar
  197. 197.
    Rojas P, Arancibia P, Bravo V, et al. Diabetes mellitus induced by olanzapine: a case report [in Spanish]. Rev Med Chil 2001; 129: 1183–5PubMedGoogle Scholar
  198. 198.
    Seaburg HL, McLendon BM, Doraiswamy PM. Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature [review]. Pharmacotherapy 2001; 21: 1448–54PubMedCrossRefGoogle Scholar
  199. 199.
    Bechara CI, Goldman-Levine JD. Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy. Pharmacotherapy 2001; 21(11): 1444–7PubMedCrossRefGoogle Scholar
  200. 200.
    Domon SE, Webber JC. Hyperglycemia and hypertriglyceridemia secondary to olanzapine. J Child Adolesc Psychopharmacol 2001; 11: 285–8PubMedCrossRefGoogle Scholar
  201. 201.
    Muench J, Carey M. Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature. J Am Board Fam Pract 2001; 14: 278–82PubMedGoogle Scholar
  202. 202.
    Kropp S, Emrich HM, Bleich S, Degner D. Olanzapine-related hyperglycemia in a nondiabetic woman [letter]. Can J Psychiatry 2001; 46: 457PubMedGoogle Scholar
  203. 203.
    Selva KA, Scott SM. Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J Pediatr 2001; 138: 936-8PubMedCrossRefGoogle Scholar
  204. 204.
    Bonanno DG, Davydov L, Botts SR. Olanzapine-induced diabetes mellitus. Ann Pharmacother 2001; 35: 563–5PubMedCrossRefGoogle Scholar
  205. 205.
    Roefaro J, Mukherjee SM. Olanzapine-induced hyperglycemic nonketonic coma. Ann Pharmacother 2001; 35: 300–2PubMedCrossRefGoogle Scholar
  206. 206.
    Bettinger TL, Mendelson SC, Dorson PG, Crismon ML. Olanzapine-induced glucose dysregulation. Ann Pharmacother 2000; 34: 865–7PubMedCrossRefGoogle Scholar
  207. 207.
    Von Hayek D, Huttl V, Reiss J, et al. [Hyperglycemia and ketoacidosis associated with olanzapine]. Nervenarzt 1999; 70: 836–7CrossRefGoogle Scholar
  208. 208.
    Lindenmayer JP, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus [letter]. Am J Psychiatry 1999; 156: 1471PubMedGoogle Scholar
  209. 209.
    Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999; 40: 438–43PubMedCrossRefGoogle Scholar
  210. 210.
    Gatta B, Rigalleau V, Gin H. Diabetic ketoacidosis with olanzapine treatment [letter]. Diabetes Care 1999; 22: 1002–3PubMedCrossRefGoogle Scholar
  211. 211.
    Ober SK, Hudak R, Rusterholtz A. Hyperglycemia and olanzapine [letter]. Am J Psychiatry 1999; 156: 970PubMedGoogle Scholar
  212. 212.
    Fertig MK, Brooks VG, Shelton PS, English CW. Hyperglycemia associated with olanzapine [letter]. J Clin Psychiatry 1998; 59: 687–9PubMedCrossRefGoogle Scholar
  213. 213.
    Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002; 63(12): 1148–55PubMedCrossRefGoogle Scholar
  214. 214.
    Rubio G, Gómez de la Cámara A, Hawkins F, et al. The risk of developing diabetes in users of atypical antipsychotics: a feasibility pilot study [abstract]. Int J Neuropsychopharmacol 2002; 5Suppl 1: S168, P.3.W.040Google Scholar
  215. 215.
    Casey D, Matchett JL, Fishman NB, Radmaker SB. The effect of antipsychotic drugs in managing diabetes [abstract]. Int J Neuropsychopharmacol 2002; 5Suppl 1: S167, P.3.W.039Google Scholar
  216. 216.
    Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63: 425–33PubMedCrossRefGoogle Scholar
  217. 217.
    Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000; 61: 742–9PubMedCrossRefGoogle Scholar
  218. 218.
    Berry S, Mahmoud R. Improvement of insulin indices after switch from olanzapine to risperidone [abstract]. Eur Neuropsychopharmacol 2002; 12Suppl 3: S316, P.2.148CrossRefGoogle Scholar
  219. 219.
    Litman R, Peterson SW, Singh I, et al. Glucose metabolism, lipid levels, and body mass indices in olanzapine-treated schizophrenia patients before and after switching to risperidone: a prospective trial [abstract]. Int J Neuropsychopharmacol 2002; 5Suppl 1: S170, P.3.W.050Google Scholar
  220. 220.
    Fuller MA, Shermock KM, Secic M, Grogg AL. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy. 2003; 23(8): 1037–43PubMedCrossRefGoogle Scholar
  221. 221.
    Gianfrancesco F, White R, Wang RH, Nasrallah HA. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003; 23(4): 328–35.PubMedCrossRefGoogle Scholar
  222. 222.
    Caro JJ, Ward A, Levinton C, Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a ret-rospective database analysis. J Clin Psychiatry 2002; 63: 1135–9PubMedCrossRefGoogle Scholar
  223. 223.
    Koro CE, Fedder DO, L’Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002; 59: 1021–6PubMedCrossRefGoogle Scholar
  224. 224.
    Farwell WR, Stump TE, Wang J, et al. Do olanzapine and risperidone cause weight gain and diabetes? [abstract]. Int J Neuropsychopharmacol 2002; 5Suppl 1: S170, P.3.W.049Google Scholar
  225. 225.
    Koro CE, Fedder DO, L’Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002; 325(7358): 243PubMedCrossRefGoogle Scholar
  226. 226.
    Glick ID, Romano SJ, Simpson G, et al. Insulin resistance in olanzapine- and ziprasidone-treated patients: results of a double-blind, controlled 6-week trial. Presented at: Annual Meeting of the American Psychiatric Association, May 5–10, 2001, New Orleans, LAGoogle Scholar
  227. 227.
    Simpson GM, Weiden P, Pigott T, et al. Ziprasidone vs olanzapine in schizophrenia: 6-month continuation study [abstract]. Eur Neuropsychopharmacol 2002; 12Suppl 3: S310, P.2.134Google Scholar
  228. 228.
    Hardy TA, Poole-Hoffmann V, Lu Y, et al. Fasting glucose and lipid changes in patients with schizophrenia treated with olanzapine or ziprasidone. Poster presented at the 42nd Annual Meeting of the American College of Neuropsychopharmacology, December 7–11, 2003, San Juan, Puerto RicoGoogle Scholar
  229. 229.
    Hardy TA, Earley W, Marquez E, et al. Oral glucose tolerance in patients treated with olanzapine 20, 30, or 40 mg/day [abstract]. Schizophr Res 2004; 67: 184, no. 373Google Scholar
  230. 230.
    Sowell MO, Mukhopadhyay N, Cavazzoni P, et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 2002; 87: 2918–23PubMedCrossRefGoogle Scholar
  231. 231.
    Sowell M, Mukhopadhyay N, Cavazzoni P, et al. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab 2003; 88(12): 5875–80PubMedCrossRefGoogle Scholar
  232. 232.
    Stoner SC, Dubisar BM, Khan R, Farrar CD. Severe hypertriglyceridemia associated with olanzapine [letter]. J Clin Psychiatry 2002; 63: 948–9PubMedCrossRefGoogle Scholar
  233. 233.
    Nguyen M, Murphy T. Olanzapine and hypertriglyceridemia [letter]. J Am Acad Child Adolesc Psychiatry 2001; 40: 133PubMedCrossRefGoogle Scholar
  234. 234.
    Sheitman BB, Bird PM, Binz W, et al. Olanzapine-induced elevation of plasma triglyceride levels [letter]. Am J Psychiatry 1999; 156: 1471–2PubMedGoogle Scholar
  235. 235.
    Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001; 21: 369–74PubMedCrossRefGoogle Scholar
  236. 236.
    Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60: 767–70PubMedCrossRefGoogle Scholar
  237. 237.
    Ishigooka J, Murasaki M, Miura S, Olanzapine Early-Phase II Study Group. Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan. Psychiatry Clin Neurosci 2001; 55: 353–63PubMedCrossRefGoogle Scholar
  238. 238.
    Hardy T, Sowell E, Marquez E, et al. Cross-sectional comparison of fasting triglycerides in normoglycemic patients with schizophrenia treated with olanzapine, risperidone, or typical antipsychotics [abstract]. Eur Neuropsychopharmacol 2003; 13Suppl 4: S339, P.2.138CrossRefGoogle Scholar
  239. 239.
    Mackell J, Leaderer M. Ziprasidone vs. olanzapine: change in CHD risk during a 6-week trial [abstract]. Schizophr Res 2004; 67: 189, no. 384Google Scholar
  240. 240.
    Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001; 158(5): 765–74PubMedCrossRefGoogle Scholar
  241. 241.
    Dimelis D, Garyfallos G, Kiouniakis F, et al. Olanzapine vs risperidone: impact on weight gain and blood lipids. Is there any relationship with antipsychotic efficacy? [abstract]. Eur Neuropsychopharmacol 2002; 12Suppl 3: S328, P.2.175CrossRefGoogle Scholar
  242. 242.
    Ozguven HD, Oner O, Baskak B, et al. The metabolic and clinical effects of olanzapine and quetiapine: preliminary findings from a randomized single-blind trial in patients with schizophrenia [abstract]. Schizophr Res 2004; 67: 190, no. 388Google Scholar
  243. 243.
    Ahl J, Kinon B, Liu-Seifert H, Baker R. Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study [abstract]. Schizophr Res 2004; 67: 179, no. 361Google Scholar
  244. 244.
    Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998; 81(4A): 18B–25BPubMedCrossRefGoogle Scholar
  245. 245.
    Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003; 28: 83–96PubMedCrossRefGoogle Scholar
  246. 246.
    Csernansky JG, Mahmoud R, Brenner R, Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346(1): 16–22PubMedCrossRefGoogle Scholar
  247. 247.
    Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407–18PubMedCrossRefGoogle Scholar
  248. 248.
    Ganguli R, Brar JS, Ayrton Z. Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. Schizophr Res 2001; 49(3): 261–7PubMedCrossRefGoogle Scholar
  249. 249.
    Fukui H, Murai T. Severe weight gain induced by combination treatment with risperidone and paroxetine. Clin Neuropharmacol 2002; 25: 269–71PubMedCrossRefGoogle Scholar
  250. 250.
    Wirshing DA, Pierre JM, Eyeler J, et al. Risperidone-associat-ed new onset diabetes. Biol Psychiatry 2001; 50: 148–9PubMedCrossRefGoogle Scholar
  251. 251.
    Croarkin PE, Jacobs KM, Bain BK. Diabetic ketoacidosis associated with risperidone treatment [letter]. Psychosomatics 2000; 41: 369–70PubMedCrossRefGoogle Scholar
  252. 252.
    Mallya A, Chawla P, Boyer SK, DeRosear L. Resolution of hyperglycemia on risperidone discontinuation: a case report [letter]. J Clin Psychiatry 2002; 63: 453–4PubMedCrossRefGoogle Scholar
  253. 253.
    Haupt DW, Newcomer JW. Reply to Croarkin et al, Letter to the Editor —Diabetic ketoacidosis associated with risperidone treatment. Psychosomatics 2001; 42: 280CrossRefGoogle Scholar
  254. 254.
    Wilson DR, D’Souza L, Sarkar N, et al. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 2002; 59: 1–6CrossRefGoogle Scholar
  255. 255.
    Cavazzoni P, Hornbuckle K, Wu J, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United Kingdom [abstract]. Int J Neuropsychopharmacol 2002; 5Suppl 1; S168, P.3.W.043Google Scholar
  256. 256.
    Martin A, L’Ecuyer S. Triglyceride, cholesterol and weight changes among risperidone treated youths. A retrospective study. Eur Child Adolesc Psychiatry 2002; 11: 129–33CrossRefGoogle Scholar
  257. 257.
    Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 2001; 24(1): 59–73CrossRefGoogle Scholar
  258. 258.
    Borison R, Arvanitis LA, Miller BG. USS ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996; 16(2): 158–69PubMedCrossRefGoogle Scholar
  259. 259.
    Arvanitis LA, Miller BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizo-phrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42: 233–46Google Scholar
  260. 260.
    Peuskens J, Link CG. A comparison of quetiapine and chlor-promazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997; 96(4): 265–73PubMedCrossRefGoogle Scholar
  261. 261.
    Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med 2000; 30(1): 95–105PubMedCrossRefGoogle Scholar
  262. 262.
    Brecher M, Rak IW, Melvin K, Jones AM. The long-term effect of quetiapine (Seroquel) monotherapy on weight in the treat-ment of schizophrenia. Int J Psych Clin Pract 2000; 4(4): 287–91CrossRefGoogle Scholar
  263. 263.
    Brecher M, Zukin S, Leong R,Osterling-Koskinen L, Jones M. Long-term weight change with quetiapine treatment in schiz-ophrenia: a comprehensive data review. Poster presented Monday, 13 December 2004 at ACNP 43rd Annual Meeting, 12–16 December 2004, San Juan, Puerto Rico. Abstract in Neuropsychopharmacology 29 (Suppl 1): S109Google Scholar
  264. 264.
    Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind com-parison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997; 54: 549–57Google Scholar
  265. 265.
    Koller EA, Weber J, Doraiswamy PM, Schneider BS. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 2004; 65(6): 857–63PubMedCrossRefGoogle Scholar
  266. 266.
    Sneed KB, Gonzalez EC. Type 2 diabetes mellitus induced by an atypical antipsychotic medication. J Am Board Fam Pract 2003; 16(3): 251–4PubMedCrossRefGoogle Scholar
  267. 267.
    Procyshyn RM, Pande S, Tse G. New-onset diabetes associated with quetiapine. Can J Psychiatry 2000; 45: 668–9PubMedGoogle Scholar
  268. 268.
    Sobel M, Jaggers ED, Franz MA. New-onset diabetes mellitus associated with the initiation of quetiapine treatment [letter]. J Clin Psychiatry 1999; 60: 556–7PubMedCrossRefGoogle Scholar
  269. 269.
    Domon SE, Cargile CS. Quetiapine-associated hyperglycemia and hypertriglyceridemia [letter]. J Am Acad Child Adolesc Psychiatry 2002; 41: 495–6PubMedCrossRefGoogle Scholar
  270. 270.
    Shaw JA, Lewis JE, Pascal S, et al. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 2001; 11: 415–24PubMedCrossRefGoogle Scholar
  271. 271.
    Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004; 64(7): 701–23PubMedCrossRefGoogle Scholar
  272. 272.
    Taylor DM, McAskill R. Atypical antipsychotics and weight gain — a systematic review. Acta Psychiatr Scand 2000; 101(6): 416–32PubMedCrossRefGoogle Scholar
  273. 273.
    Wetterling T, Mussigbrodt HE. Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol 1999; 19(4): 316–21PubMedCrossRefGoogle Scholar
  274. 274.
    Palmgren K, Wighton A, Reynolds CW, et al. The safety and efficacy of zotepine in the treatment of schizophrenia: results of a one-year naturalistic clinical trial. Int J Psych Clin Pract 2000; 4: 299–306CrossRefGoogle Scholar
  275. 275.
    Prakash A, Lamb HM. Zotepine: a review of its pharmacody-namic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 1998; 9: 153–75CrossRefGoogle Scholar
  276. 276.
    Wetterling T. Hyperlipidemia: side-effect of the treatment with an atypical antipsychotic (zotepine)? [in German]. Psychiatr Prax 2002; 29(8): 438–40PubMedCrossRefGoogle Scholar
  277. 277.
    Peuskens J, Bech P, Moller HJ, et al. Amisulpride vs risperidone in the treatment of acute exacerbation of schizophrenia. Amisulpride study group. Psychiatry Res 1999; 88: 107–17Google Scholar
  278. 278.
    Mortimer A, Martin S, Loo H, et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia: SOLIANOL Study Group. Int Clin Psychopharmacol 2004; 19: 63–9PubMedCrossRefGoogle Scholar
  279. 279.
    Daniel DG, Zimbroff DL, Potkin SG, et al., and the Ziprasidone Study Group. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999; 20: 491–505PubMedCrossRefGoogle Scholar
  280. 280.
    Hirsch SR, Kissling W, Bauml J, et al. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002; 63(6): 516–23PubMedCrossRefGoogle Scholar
  281. 281.
    Arato M, O’Connor R, Meltzer HY,ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002; 17(5): 207–15PubMedCrossRefGoogle Scholar
  282. 282.
    Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003; 23(6): 595–600PubMedCrossRefGoogle Scholar
  283. 283.
    Cohen S, Fitzgerald B, Okos A, et al. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. J Clin Psychiatry 2003; 64: 60–2PubMedCrossRefGoogle Scholar
  284. 284.
    Kingsbury SJ, Fayek M, Trufasiu D, et al. The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry 2001; 62: 347–9PubMedCrossRefGoogle Scholar
  285. 285.
    Yang SH, McNeely MJ. Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone [letter]. Am J Psychiatry 2002; 159: 1435PubMedCrossRefGoogle Scholar
  286. 286.
    Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia [review]. Clin Ther 2002; 24: 21–37PubMedCrossRefGoogle Scholar
  287. 287.
    Romano S, Cutler N, Weiden PJ, Simpson GM. Ziprasidone’s effects on weight and lipids in patients with schizophrenia [abstract]. Int J Neuropsychopharmacol 2002; 5Suppl 1: S171,P.3.W.055Google Scholar
  288. 288.
    Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003; 6(4): 325–37Google Scholar
  289. 289.
    Pigott TA, Carson WH, Saha AR, et al. for the Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003; 64: 1048–56Google Scholar
  290. 290.
    McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004; 65 Suppl 18: 47–56 291.Cornblatt B, Kern RS, Carson WH, et al. Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis. Int J Neuropsychopharmacol 2002; 5 Suppl 1: S185Google Scholar
  291. 291.
    Cornblatt B, Kern RS, Carson WH, et al. Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis. Int J Neuropsychopharmacol 2002; 5 Suppl 1: S185Google Scholar
  292. 292.
    McQuade RD, Marcus R, Sanchez R, et al, Aripiprazole versus placebo in acute mania: safety and tolerability pooled analysis. Poster presented at the 5th International Conference on Bipolar Disorder, June 12–14, 2003, Pittsburgh, PAGoogle Scholar
  293. 293.
    Keck Jr PE, Marcus R, Tourkodimitris S, et al,,Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160(9): 1651–8PubMedCrossRefGoogle Scholar
  294. 294.
    Lorenzo C, Okoloise M, Williams K, et al.; San Antonio Heart Study. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 2003; 26(11): 3153–9PubMedCrossRefGoogle Scholar
  295. 295.
    Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108(4): 414–9PubMedCrossRefGoogle Scholar
  296. 296.
    L’Italien GJ. Pharmacoeconomic impact of antipsychotic-induced metabolic events. Prev Med Manag Care 2003; 3(2 Suppl): S38–S42.Google Scholar
  297. 297.
    Casey D, L’Italian G, Waldeck R, et al. Metabolic syndrome comparison between olanzapine, aripiprazole and placebo. Poster presented at the American Psychiatric Association, May 2003, San Francisco, CAGoogle Scholar
  298. 298.
    Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334-9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Department of PsychiatryWashington University School of MedicineSt. LouisUSA

Personalised recommendations